AbbVie (ABBV) Total Current Liabilities (2012 - 2026)
AbbVie (ABBV) posted quarterly Total Current Liabilities of $42.1 billion for Q1 2026, up 15.65% year-over-year from $36.4 billion in Q1 2025, and down 2.75% quarter-over-quarter from $43.3 billion in Q4 2025.
AbbVie (ABBV) Total Current Liabilities (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has reported Total Current Liabilities for 15 consecutive years, with $42.1 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities rose 15.65% year-over-year to $42.1 billion; the TTM figure through Mar 2026 stood at $42.1 billion (up 15.65% YoY), while the FY2025 annual figure was $43.3 billion, up 11.72% from the prior year.
- Total Current Liabilities declined to $42.1 billion in Q1 2026 per ABBV's latest filing, from $43.3 billion in the prior quarter.
- Across five years, Total Current Liabilities topped out at $43.3 billion in Q4 2025 and bottomed at $27.6 billion in Q1 2023.
- Historically, Total Current Liabilities has averaged $36.9 billion across 5 years, with a median of $37.8 billion in 2023.
- Annual changes were most pronounced in 2022 — Total Current Liabilities retreated 16.07% — and 2024, when it jumped 50.5%.
- AbbVie's Total Current Liabilities stood at $29.5 billion in 2022, then rose by 28.11% to $37.8 billion in 2023, then increased by 2.4% to $38.7 billion in 2024, then increased by 11.72% to $43.3 billion in 2025, then decreased by 2.75% to $42.1 billion in 2026.
- Business Quant data shows ABBV's Total Current Liabilities at $42.1 billion in Q1 2026, $43.3 billion in Q4 2025, and $39.4 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 54.90 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 41.64 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 27.73 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 31.75 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 31.55 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 25.50 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 11.02 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 32.65 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -28.89 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 37.11 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 41.64 Bn |
| Mar 31, 2026 | 42.10 Bn |
| Dec 31, 2025 | 43.29 Bn |
| Sep 30, 2025 | 39.39 Bn |
| Jun 30, 2025 | 39.77 Bn |
| Mar 31, 2025 | 36.40 Bn |
| Dec 31, 2024 | 38.75 Bn |
| Sep 30, 2024 | 43.06 Bn |
| Jun 30, 2024 | 41.92 Bn |
| Mar 31, 2024 | 41.52 Bn |
| Dec 31, 2023 | 37.84 Bn |
| Sep 30, 2023 | 34.77 Bn |
| Jun 30, 2023 | 32.24 Bn |
| Mar 31, 2023 | 27.59 Bn |
| Dec 31, 2022 | 29.54 Bn |
| Sep 30, 2022 | 32.71 Bn |
| Jun 30, 2022 | 34.47 Bn |
| Mar 31, 2022 | 32.52 Bn |
| Dec 31, 2021 | 35.19 Bn |
| Sep 30, 2021 | 28.53 Bn |